Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 5, 2015, Pages 382-391

  Porrini, Esteban ^a   Ruggenenti, Piero ^b   Mogensen, Carl Erik ^c   Barlovic, Drazenka Pongrac ^d   Praga, Manuel ^e   Cruzado, Josep M ^f   Hojs, Radovan ^g   Abbate, Manuela ^c   de Vries, Aiko P J ^h  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALBUMINURIA; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; GENETIC HETEROGENEITY; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MACROALBUMINURIA; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SEX; ANIMAL; COMPLICATION; FEMALE; MALE; PATHOPHYSIOLOGY; URINE;

ALBUMINURIA; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PHENOTYPE; RISK FACTORS;

EID: 84928639122     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00094-7     Document Type: Note

References (91)

1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385:117-171.
2. (accessed April 4, 2015). https://www.renalreg.org/reports/2014-seventeenth-annual-report/.
3. Schaubel DE, Morrison HI, Desmeules M, Parsons DA, Fenton SS End-stage renal disease in Canada: prevalence projections to 2005. CMAJ 1999, 160:1557-1563.
4. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005, 48:17-26.
5. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011, 305:2532-2539.
6. Gregg E, Yanfeng L, Wang J, et al. Changes in diabetes-related complications in the Unites States, 1990-2010. N Engl J Med 2014, 17:1514-1523.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. the RENAAL Study Investigators.
8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. the Collaborative Study Group.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. the The Collaborative Study Group.
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
11. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998, 352:1252-1256. on behalf of Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
12. Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999, 10:997-1006.
13. Schieppati A, Remuzzi G The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int 2003, 64:1947-1955.
14. Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011, 58:776-783. the DEMAND Study Investigators.
15. Remuzzi G, Schieppati A, Ruggenenti P Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145-1151.
16. Mogensen CE, Christensen CK, Vittinghus E The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983, 32(suppl 2):64-78.
17. Kramer HJ, Nguyen QD, Curhan G, Hsu CY Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289:3273-3277.
18. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004, 27:195-200.
19. So WY, Kong AP, Ma RC, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006, 29:2046-2052.
20. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009, 24:1212-1219. the Japan Diabetes Clinical Data Management Study Group.
21. Thomas MC, MacIsaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009, 32:1497-1502.
22. Penno G, Solini A, Bonora E, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011, 29:1802-1809. the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.
23. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study. Cardiorenal Med 2012, 2:1-10.
24. Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL, Kshirsagar AV Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 2013, 27:123-127.
25. Boronat M, García-Cantón C, Quevedo V, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail 2014, 36:166-170.
26. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006, 55:1832-1839. the UKPDS Study Group.
27. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008, 168:2440-2447.
28. Afghahi H, Cederholm J, Eliasson B, et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes-the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant 2011, 26:1236-1243.
29. Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012, 35:2061-2068. the GFR Study Investigators.
30. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976, 31:155-163.
31. Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 2006, 29:1024-1030.
32. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000, 35:1155-1165.
33. Gaspari F, Ruggenenti P, Porrini E, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013, 84:164-173. the GFR Study Investigators.
34. MacIsaac RJ, Ekinci EI, Jerums G Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014, 63(suppl 2):S39-S62.
35. Harjutsalo V, Groop PH Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis 2014, 21:260-266.
36. Berg UB Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 2006, 21:2577-2582.
37. Neugarten J, Acharya A, Silbiger SR Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000, 11:319-329.
38. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 63:1499-1507. the RENAAL Study Investigators.
39. Halbesma N, Brantsma AH, Bakker SJ, et al. Gender differences in predictors of the decline of renal function in the general population. Kidney Int 2008, 74:505-512. the PREVEND study group.
40. Jelinsky SA, Harris HA, Brown EL, et al. Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney. Endocrinology 2003, 144:701-710.
41. Dixon A, Maric C 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol Renal Physiol 2007, 293:F1678-F1690.
42. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension 2001, 37:645-650.
43. Baylis C Sexual dimorphism in the aging kidney: differences in the nitric oxide system. Nat Rev Nephrol 2009, 5:384-396.
44. Diamond-Stanic MK, You YH, Sharma K Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol 2012, 32:261-268.
45. Johnson PR, Stern JS, Horwitz BA, Harris RE, Greene SF Longevity in obese and lean male and female rats of the Zucker strain: prevention of hyperphagia. Am J Clin Nutr 1997, 66:890-903.
46. Gades MD, Stern JS, van Goor H, Nguyen D, Johnson PR, Kaysen GA Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int 1998, 53:130-135.
47. Stevenson FT, Wheeldon CM, Gades MD, Kaysen GA, Stern JS, van Goor H Estrogen worsens incipient hypertriglyceridemic glomerular injury in the obese Zucker rat. Kidney Int 2000, 57:1927-1935.
48. Yu M, Ryu DR, Kim SJ, Choi KB, Kang DH Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey. Nephrol Dial Transplant 2010, 25:469-477.
49. Li Y, Zhao L, Chen Y, et al. Association between metabolic syndrome and chronic kidney disease in perimenopausal women. Int J Environ Res Public Health 2013, 10:3987-3997.
50. Szekacs B, Vajo Z, Varbiro S, et al. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG 2000, 107:1017-1021.
51. Fenkci S, Fenkci V, Yilmazer M, Serteser M, Koken T Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension. Hum Reprod 2003, 18:866-870.
52. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD HRT does not improve urinary albumin excretion in postmenopausal diabetic women. Diabetes Res Clin Pract 2003, 60:33-39.
53. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001, 161:2000-2005. the Prevention of Renal and Vascular End Stage Disease Study Group.
54. Agarwal M, Selvan V, Freedman BI, Liu Y, Wagenknecht LE The relationship between albuminuria and hormone therapy in postmenopausal women. Am J Kidney Dis 2005, 45:1019-1025.
55. Ahmed SB, Culleton BF, Tonelli M, et al. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 2008, 74:370-376. the Alberta Kidney Disease Network.
56. Kurella M, Lo JC, Chertow GM Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005, 16:2134-2140.
57. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004, 140:167-174.
58. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006, 95:136-147.
59. Szalat A, Raz I Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab 2008, 10:1135-1156.
60. Thorand B, Baumert J, Döring A, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006, 184:216-224. the KORA Group.
61. Thorand B, Baumert J, Kolb H, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007, 30:854-860.
62. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004, 27:2898-2904.
63. Lee C, Joseph L, Colosimo A, Dasgupta K Mortality in diabetes compared with previous cardiovascular disease: a gender-specific meta-analysis. Diabetes Metab 2012, 38:420-427.
64. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821.
65. Gall MA, Rossing P, Skøtt P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991, 34:655-661.
66. Penno G, Solini A, Zoppini G, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Care 2012, 35:2317-2323. the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.
67. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?. Diabetes Care 2006, 29:1560-1566.
68. Griffin KA, Kramer H, Bidani AK Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008, 294:F685-F696.
69. Palatini P, Mormino P, Dorigatti F, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006, 70:578-584. the HARVEST Study Group.
70. Wiseman MJ, Saunders AJ, Keen H, Viberti G Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 1985, 312:617-621.
71. Sarafidis PA, Ruilope LM Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006, 26:232-244.
72. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981, 241:F85-F93.
73. Mogensen CE Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest 1971, 28:91-100.
74. Mogensen CE Glomerular filtration rate and renal plasma flow in normal and diabetic man during elevation of blood sugar levels. Scand J Clin Lab Invest 1971, 28:177-182.
75. Premaratne E, Macisaac RJ, Tsalamandris C, Panagiotopoulos S, Smith T, Jerums G Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia 2005, 48:2486-2493.
76. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
77. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951. the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators.
78. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
79. Ruggenenti P, Remuzzi G Time to abandon microalbuminuria?. Kidney Int 2006, 70:1214-1222.
80. IDF worldwide definition of the metabolic syndrome International Diabetes Federation, (accessed April 4, 2015). http://www.idf.org/metabolic-syndrome.
81. Ruggenenti P, Porrini E, Motterlini N, et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 2012, 23:1717-1724. the BENEDICT Study Investigators.
82. Caramori ML, Fioretto P, Mauer M The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. Diabetes 2000, 49:1399-1408.
83. Fioretto P, Caramori ML, Mauer M The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 2008, 51:1347-1355.
84. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010, 21:556-563. the Renal Pathology Society.
85. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996, 39:1569-1576.
86. Budhiraja P, Thajudeen B, Popovtzer M Absence of albuminuria in type 2 diabetics with classical diabetic nephropathy: Clinical pathological study. J Biomed Sci Eng 2013, 6:20-25.
87. Chawla V, Roshan B Non-proteinuric diabetic nephropathy. Curr Diab Rep 2014, 14:529.
88. Tonolo G, Cherchi S Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis 2014, 7:107-115.
89. de Vries AP, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol 2014, 2:417-426. the ERA-EDTA Working Group Diabesity.
90. Halimi JM The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab 2012, 38:291-297.
91. Costacou T, Fried L, Ellis D, Orchard TJ Sex differences in the development of kidney disease in individuals with type 1 diabetes mellitus: a contemporary analysis. Am J Kidney Dis 2011, 58:565-573.